Entity

Time filter

Source Type

Le Touquet – Paris-Plage, France

Combadiere B.,University Pierre and Marie Curie | Combadiere B.,Laboratory of Immunity and Infection | Siberil S.,University Pierre and Marie Curie | Duffy D.,University Pierre and Marie Curie
Pathologie Biologie | Year: 2010

Protection against pathogens is mediated by both humoral responses (neutralizing antibodies) and cellular immunity, both CD4+ and CD8+ cells. In the case of influenza viruses, circulating strains contain both variable and conserved T and B cell epitopes that are challenged after vaccination and/or infection. During infection, the role of T cells is to prevent viral dissemination in the organism by killing the infected cells and helping B cell antibody production to neutralize the virus. The threat of influenza virus increases the preparedness of protective immunity to pandemic and seasonal infection by vaccination. Several questions remain that need to be further addressed for the future development of innovative and rapidly efficient vaccines strategies. Firstly, what are the correlates of long-term protection (antibodies and/or T cells) against variant strains of influenza? How does the individual factors (age, natural immunity, vaccination and/or infection history) influence the generation and maintenance of memory cells? What are the factors allowing the maintenance of immune memory (regular contact with the pathogen or re-vaccination)? Secondly, what is the nature and quality (function / phenotype / location) of memory B and T cells? Finally, is it necessary to induce and maintain immunological memory against conserved proteins and/or to re-vaccinate against viral variants? What would be the consequences of repeated vaccination? These questions remain a subject of debate that will be further discussed. Since immunological memory is the cornerstone of vaccination, it is essential that we have a better understanding of its generation and maintenance over time as well as its contribution to recall responses during pandemics or after vaccination. © 2010 Elsevier Masson SAS. Source


Combadiere B.,French Institute of Health and Medical Research | Combadiere B.,University Pierre and Marie Curie | Combadiere B.,Laboratory of Immunity and Infection | Vogt A.,Charite - Medical University of Berlin | And 20 more authors.
PLoS ONE | Year: 2010

Background:Current conventional vaccination approaches do not induce potent CD8 T-cell responses for fighting mostly variable viral diseases such as influenza, avian influenza viruses or HIV. Following our recent study on vaccine penetration by targeting of vaccine to human hair follicular ducts surrounded by Langerhans cells, we tested in the first randomized Phase-Ia trial based on hair follicle penetration (namely transcutaneous route) the induction of virus-specific CD8 T cell responses. Methods and Findings: We chose the inactivated influenza vaccine - a conventional licensed tetanus/influenza (TETAGRIP®) vaccine - to compare the safety and immunogenicity of transcutaneous (TC) versus IM immunization in two randomized controlled, multi-center Phase I trials including 24 healthy-volunteers and 12 HIV-infected patients. Vaccination was performed by application of inactivated influenza vaccine according to a standard protocol allowing the opening of the hair duct for the TC route or needle-injection for the IM route. We demonstrated that the safety of the two routes was similar. We showed the superiority of TC application, but not the IM route, to induce a significant increase in influenza-specific CD8 cytokine-producing cells in healthy-volunteers and in HIV-infected patients. However, these routes did not differ significantly for the induction of influenza-specific CD4 responses, and neutralizing antibodies were induced only by the IM route. The CD8 cell response is thus the major immune response observed after TC vaccination. Conclusions: This Phase Ia clinical trial (Manon05) testing an anti-influenza vaccine demonstrated that vaccines designed for antibody induction by the IM route, generate vaccine-specific CD8 T cells when administered transcutaneously. These results underline the necessity of adapting vaccination strategies to control complex infectious diseases when CD8 cellular responses are crucial. Our work opens up a key area for the development of preventive and therapeutic vaccines for diseases in which CD8 cells play a crucial role. © 2010 Combadière et al. Source

Discover hidden collaborations